Anti-CD25 Humanized monoclonal antibody used for immunosuppression in organ Transplant patient is:

Correct Answer: Basiliximab
Description: Basiliximab is an Anti-CD25 Antibody (IL-2 receptor antagonists used for immunosuppression in organ transplant patiennts. Monoclonal Antibodies as Immunosuppressive agents in Organ Transplantation: Anti-CD3- Muromonab-CD3 Anti-CD20-Rituximab Anti-CD25 (IL 2 receptor)- Basiliximab(Chimeric), Daclizumab(Humanized) Anti-CD52-Alemtuzumab Drug (Trade name) Target Monoclonal Antibody Type Mechanism Muromonab-CD3 (Ohoclone OKT3) Anti-CD3 Murine(Mouse) Monoclonal antibody Binds CD3 associated with the TCR, leading to initial activation and cytokine release, followed by blockade of function, lysis and T cell depletion Rituximab (Rituxan) Anti-CD20 Recombinant Chimeric Monoclonal antibody Binds to CD20 on B cells and causes depletion Basiliximab (Simulect) Anti-CD25 Recombinant Chimeric Monoclonal Antibody Binds to high-affinity chain of IL-2 Receptors (CD25) on activated T cells, causing depletion and preventing IL-2 mediated activation Daclizumab (Zenopax) Anti-CD25 Recombinant Humanized Monoclonal Antibody Similar to that of Basiliximab Alemtuzumab (Campath-1h) Anti-CD52 Recombinant Humanized Monoclonal Antibody Binds to CD52 expressed on most T and B cells, monocytes, macrophages, and NK cells, causing lysis and prolonged depletion Ref: KDT 7th edition Pgno: 878
Category: Pharmacology
Share:

Get More
Subject Mock Tests

Practice with over 200,000 questions from various medical subjects and improve your knowledge.

Attempt a mock test now
Mock Exam

Take an exam with 100 random questions selected from all subjects to test your knowledge.

Coming Soon
Get More
Subject Mock Tests

Try practicing mock tests with over 200,000 questions from various medical subjects.

Attempt a mock test now
Mock Exam

Attempt an exam of 100 questions randomly chosen from all subjects.

Coming Soon
WordPress › Error

There has been a critical error on this website.

Learn more about troubleshooting WordPress.